Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 3.78IPCO.TO 0.08DC.A.TO 0.1NESN-SIX 0MCK 9.94GOOG -1.89XLV -0.22TEVA 0.83
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.06
+0.09 (0.32%)
as of Aug 25, 2026, 2:11:02 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
TOP PICK

Pfizer Inc(PFE)

Sep 10, 2001
Prefers this and American Home over Lilly. Good product line.
Photo of Brad WillockBrad WillockUnlock Rating
$38.17

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 30, 2001
Aging population. Nine new drugs coming out in the next 3 years. Great pipeline. 40% growth.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$38.30

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Aug 14, 2001
(Was a top pick on Apr 12/01 even) Still a big fan. Good sector to be in. Strong pipeline. Reports are good. Good price.
Photo of Neil MurdockNeil MurdockUnlock Rating
$41.07

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 08, 2001
Have a tremendous pipeline for new drugs.
Photo of Rob CallanderRob CallanderUnlock Rating
$40.10

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 18, 2001
Good short/long term growth potential. Great pipeline.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$41.01

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 12, 2001
Suspicious of large cap drug companies. High risk industry.
Photo of David BaskinDavid BaskinUnlock Rating
$37.60

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Jun 20, 2001
A little high now. Buy below $40.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$44.50

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 14, 2001
(Was a top pick on Jan 8/01 up 2%) Prefers over Merck. Less patent expiries. In a good position with good pipeline.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$43.25

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jun 06, 2001
Likes both Pfizer and Merck in pharmaceuticals.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$42.85

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 05, 2001
Caution. At its FMV.
Photo of Ross HealyRoss HealyUnlock Rating
$42.95

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 28, 2001
Least amount of patent expiry. Have some good new product launches. Good pipeline.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$41.86

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 25, 2001
Always expensive, but a good pipeline. Long term.
Photo of John ZechnerJohn ZechnerUnlock Rating
$41.86

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 17, 2001
Prefers over Merck. No patent expiries.
Photo of John McCollJohn McCollUnlock Rating
$44.76

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 16, 2001
(Was a top pick on Apr 27/00 up 3.3%) Still likes.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$44.62

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 10, 2001
Great pipeline of drugs. Good synergies. Safe play. Price a little high.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$43.74

Stock price when the opinion was issued

$28.48

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 856 to 870 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -2.98$99.89
TFPM 0$
OGC.TO -0.83$42.39
SLB 0.045$54.045
ARG.TO 0.33$8.55

Today's Top Picks

SII.TO 3.78$190.97
IPCO.TO 0.08$35.3
DC.A.TO 0.1$5.25
NESN-SIX 0$
MCK 9.94$883.73

Popular Articles

Latest Sell Signals

RKLB -1.05$67.23
INTC 1.21$88.47
MSFT 1.63$488.94
WSP.TO -0.96$191.32
CLS.TO 10.72$418.08

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like